Gilead execs tick off its three top areas of M&A interest

Now that Gilead ($GILD) faces increased competition for its goliath share of the U.S. hep C market with Merck's ($MRK) fresh arrival on the scene, the Big Biotech is keeping a mental checklist of potential new collaborations and acquisitions that might help rev up some added excitement for the company's shares. In its review of annual numbers on Tuesday night, Gilead's John Milligan--soon to be CEO--cited three key areas of interest: oncology, inflammatory diseases and liver diseases. Story

Suggested Articles

AstraZeneca is confident data generated across development show the antibody works despite a pivotal study missing its primary endpoint.

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.